Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life

References

• Farmakis D, Porter J, Taher A, et al. 2021. Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022;6(8):e732. doi: 10.1097/HS9.0000000000000732. PMID: 35928543; PMCID: PMC9345633.
   Google Scholar
• Dhanya R, Sedai A, Ankita K, et al. Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India. Blood Adv. 2020;4(7):1448–1457. doi: 10.1182/bloodadvances.2019000760.
   PubMed Web of Science ®Google Scholar
• Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652–656. doi: 10.1172/JCI111464.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Cappellini MD, et al. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013;121(12):2199–2212; quiz 2372. doi: 10.1182/blood-2012-10-408021.
   PubMed Web of Science ®Google Scholar
• Karimi M. Hydroxyurea in the management of thalassemia intermedia. Hemoglobin. 2009;33(suppl 1):S177–S82. doi: 10.3109/03630260903351809.
   PubMedGoogle Scholar
• Ansari SH, Lassi ZS, Khowaja SM, et al. Hydroxyurea [hydroxycarbamide] for transfusion-dependent β-thalassaemia. Cochrane Database Syst Rev. 2019;3(3):CD012064. doi: 10.1002/14651858.CD012064.pub2.
   PubMedGoogle Scholar
• Biswas S, Nag A, Ghosh K, et al. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia. Ann Hematol. 2019;98(2):289–299. doi: 10.1007/s00277-018-3536-x.
   PubMed Web of Science ®Google Scholar
• Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, et al. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol Dis. 2008;41(1):136–137. doi: 10.1016/j.bcmd.2008.03.001.
   PubMed Web of Science ®Google Scholar
• Masera N, Tavecchia L, Capra M, et al. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus. 2010;8(1):63–65.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wei Z, Yang G, et al. Investigating the efficacy and safety of thalidomide for treating patients with ß-thalassemia: a meta-analysis. Front Pharmacol. 2021;12:814302. doi: 10.3389/fphar.2021.814302.
   PubMed Web of Science ®Google Scholar
• Nag A, Radhakrishnan VS, Kumar J, et al. Thalidomide in patients with transfusion-dependent E-beta thalassemia refractory to hydroxyurea: a single-center experience. Indian J Hematol Blood Transfus. 2020;36(2):399–402. doi: 10.1007/s12288-020-01263-2.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhu W, Cai N, et al. Thalidomide induces haematologic responses in patients with β-thalassaemia. Eur J Haematol. 2017;99(5):437–441. doi: 10.1111/ejh.12955.
   PubMed Web of Science ®Google Scholar
• Yassin AK. Promising response to thalidomide in symptomatic β-thalassemia. Indian J Hematol Blood Transfus. 2020;36(2):337–341. doi: 10.1007/s12288-019-01231-5.
   PubMed Web of Science ®Google Scholar
• Fard AD, Hosseini SA, Shahjahani M, et al. Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res. 2013;7(3):47–54. Vol.
   PubMedGoogle Scholar
• Siddiqui SH, Ishtiaq R, Sajid F, et al. Quality of life in patients with thalassemia major in a developing country. J Coll Physicians Surg–Pak. 2014;24(7):477–480.
   PubMed Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The MOS 36-item short-form health survey [SF-36]. I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
   PubMed Web of Science ®Google Scholar
• Kalantri SA, Ray R, Chattopadhyay A, et al. Efficacy of decitabine as hemoglobin F inducer in HbE/β-thalassemia. Ann Hematol. 2018;97(9):1689–1694. doi: 10.1007/s00277-018-3357-y.
   PubMed Web of Science ®Google Scholar
• Shah S, Sheth R, Shah K, et al. Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study. Br J Haematol. 2020;188(3):e18–21–e21. doi: 10.1111/bjh.16272.
   Web of Science ®Google Scholar
• Bhurani D, Kapoor J, Yadav N, et al. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients. Ann Hematol. 2021;100(6):1417–1427. doi: 10.1007/s00277-021-04501-3.
   PubMed Web of Science ®Google Scholar
• Ansari SH, Ansari I, Wasim M, et al. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. Blood Adv. 2022;6(24):6162–6168. doi: 10.1182/bloodadvances.2022007031.
   PubMed Web of Science ®Google Scholar
• Yang K, Wu Y, Zhou Y, et al. Thalidomide for patients with β-thalassemia: a multicenter experience. Mediterr J Hematol Infect Dis. 2020;12(1):e2020021. doi: 10.4084/MJHID.2020.021.
   PubMedGoogle Scholar
• Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in β thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1-2):10–15. doi: 10.1016/j.cca.2009.06.019.
   PubMed Web of Science ®Google Scholar
• Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–1836. doi: 10.1111/j.1537-2995.2007.01399.x.
   PubMed Web of Science ®Google Scholar
• Telfer P, Constantinidou G, Andreou P, et al. Quality of life in thalassemia. Ann N Y Acad Sci. 2005;1054(1):273–282. doi: 10.1196/annals.1345.035.
   PubMedGoogle Scholar
• Ansari S, Baghersalimi A, Azarkeivan A, et al. Quality of life in patients with thalassemia major. Iran J Pediatr Hematol Oncol. 2014;4(2):57–63.
   PubMedGoogle Scholar
• Rodigari F, Brugnera G, Colombatti R. Health-related quality of life in hemoglobinopathies: A systematic review from a global perspective. Front Pediatr. 2022;10:886674. doi: 10.3389/fped.2022.886674.
   PubMed Web of Science ®Google Scholar